Deciding whether to purchase shares of Krystal Biotech requires a careful, individualized evaluation of your personal risk tolerance, investment horizon, and portfolio strategy. Proponents of the stock point to its rare financial profile for a biotech firm—highlighting consistent profitability, high gross margins, a growing global commercial footprint for VYJUVEK, and a proprietary technology platform capable of expanding into diverse therapeutic areas. Conversely, cautious investors note potential near-term risks, such as product revenue concentration around a single commercial therapy, the unpredictability of international pricing and reimbursement negotiations in Europe and Asia, and the inherent clinical trial risks associated with expanding into new pipeline indications. Conducting thorough fundamental research and consulting professional financial advisors is essential before committing capital.